Brandywine Global Investment Management LLC Cuts Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Brandywine Global Investment Management LLC trimmed its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 59.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,971 shares of the specialty pharmaceutical company’s stock after selling 149,402 shares during the period. Brandywine Global Investment Management LLC owned about 0.31% of Collegium Pharmaceutical worth $2,893,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in COLL. Principal Financial Group Inc. grew its stake in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after acquiring an additional 64,958 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after purchasing an additional 5,464 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 4.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company’s stock worth $14,741,000 after purchasing an additional 16,655 shares during the last quarter. Royce & Associates LP lifted its position in shares of Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company’s stock worth $9,728,000 after buying an additional 33,674 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after buying an additional 175,892 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on COLL. Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Insider Activity

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares of the company’s stock, valued at $3,732,630. The trade was a 1.78 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is currently owned by insiders.

Collegium Pharmaceutical Stock Up 2.1 %

Shares of COLL opened at $30.00 on Thursday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The business has a fifty day moving average of $30.16 and a 200 day moving average of $32.28. The company has a market cap of $944.58 million, a PE ratio of 12.93 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. On average, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.